spacer
home > ict > autumn 2019 > a landmark for life science professionals
PUBLICATIONS
International Clinical Trials

A Landmark for Life Science Professionals





DIA Europe 2020 is more than an annual meeting in Europe; it reflects DIA’s strategic initiatives across several thought leadership streams, including clinical development and operations, regulatory science and operations, value and access, medical affairs, and many others. However, it’s not enough to talk about thought leadership; at this stage, it’s important to ground it in what and who we are bringing to the table. First of all, being a ‘patients included’ event, we embed patient engagement in all content tracks, and Matthieu Boudes, PPP Coordinator at the European Patients’ Forum, has already spoken very highly of the importance of this meeting to patient representatives. He cited, as main reasons, “The 20 ICT l November 2019 ICT Spotlight DIA Europe 2020 will take place on 17-19 March in Brussels, at the start of a new fiveyear EU cycle. There's no better place or time to get valuable insights from key regulators and industry leaders from across the full spectrum of medicines development A Landmark for Life Science Professionals SP TLIGHT www.samedanltd.com l ICT 21 DIA Europe has become a landmark, must-attend event for life science professionals from across the entire drug development spectrum − from discovery to marketed use – to facilitate open collaboration by incorporating representatives from the full life science landscape. DIA ensures that industry, payers, patients, and regulators all have an equal voice. Thought-provoking worldwide issues will be deconstructed by acclaimed panellists representing multiple stakeholders from around the world in this growing ecosystem of life sciences. fantastic networking opportunity,” as well as “the outstanding programme and its diversity, covering all aspects of medicines development, from regulatory decisions, policy and digital innovation, to patient centricity”.

The importance of the latter point to pharmaceutical development and information sharing is in an upward trend, making it the central topic of a session chaired by PMDA International Programmes Director Junko Sato, where several heads of regulatory agencies from around the world will share their key findings on how to drive patient centricity, stemming from their clinical and regulatory experiences.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the company

DIA Europe has become a landmark, must-attend event for life science professionals from across the entire drug development spectrum − from discovery to marketed use – to facilitate open collaboration by incorporating representatives from the full life science landscape. DIA ensures that industry, payers, patients, and regulators all have an equal voice. Thought-provoking worldwide issues will be deconstructed by acclaimed panellists representing multiple stakeholders from around the world in this growing ecosystem of life sciences.
Print this page
Send to a friend
Privacy statement
News and Press Releases

ICON Releases Environmental, Social and Governance Report

ICON announced today the release of its 2020 Environmental, Social and Governance (ESG) Report.
More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement